Cite
HARVARD Citation
Tanaka, Y. et al. (2021). A phase 2 study of E6011, an anti-Fractalkine monoclonal antibody, in patients with rheumatoid arthritis inadequately responding to biological disease-modifying antirheumatic drugs. Modern rheumatology. 31 (4), pp. 783-789. [Online].